IGM Biosciences Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 09, 2022 16:16 ET
|
IGM Biosciences, Inc.
– Closing of Global Collaboration Agreement with Sanofi; $150 Million Upfront Payment to IGM – – Completed Public Equity Offering with Gross Proceeds of $230 Million – – Continued Advancement in...
IGM Biosciences Announces Closing of Global Collaboration Agreement with Sanofi
May 06, 2022 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Announces Closing of $230.0 Million Public Offering
April 06, 2022 16:39 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing on April 1, 2022 of its previously announced underwritten public offering...
IGM Announces Pricing of $200.0 Million Public Offering
March 30, 2022 00:56 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the pricing of its underwritten public offering of 8,695,653 shares of its non-voting...
IGM Announces Proposed Public Offering
March 29, 2022 07:41 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell $200.0 million of shares of its common stock and, in...
IGM Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 29, 2022 06:01 ET
|
IGM Biosciences, Inc.
– Announced Global Collaboration Agreement with Sanofi for Oncology, Autoimmune and Inflammation Targets; IGM to Receive $150 Million Upfront Payment and potentially more than $6 Billion in Aggregate...
IGM Biosciences to Host Conference Call and Webcast Today to Discuss Global Collaboration Agreement with Sanofi
March 29, 2022 02:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Advances Novel Antibody IGM-6268 Into Clinical Trials for the Treatment and Prevention of COVID-19
February 09, 2022 07:00 ET
|
IGM Biosciences, Inc.
– In vitro studies indicate IGM-6268 exhibits potent neutralization activity against the Omicron variant and all other Variants of Concern and Variants of Interest tested – – IGM-6268 Phase 1...
IGM Biosciences to Present at the Guggenheim 2022 Oncology Conference
February 03, 2022 16:05 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...